Do you want to read an article? Please log in or register.
Responsiveness and minimal clinically important difference of SGRQ-I and K-BILD in idiopathic pulmonary fibrosis
Interstitial Lung DiseasePulmonary Fibrosis
RECOMMENDED
Related content
RECOMMENDED
Bronchi
Anxiety and depression in bronchiectasis: Response to pulmonary rehabilitation and minimal clinically important difference of the Hospital Anxiety and Depression Scale
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Chron Respir Dis.
Wynne SC, Patel S, Barker RE, Jones SE, Walsh JA, Kon SS, Cairn J, Loebinger MR, Wilson R, Man WD, Nolan CM
doi: 10.1177/1479973120933292.
RECOMMENDED
Pulmonary Fibrosis
Differences in clinical characteristics and outcomes between men and women with idiopathic pulmonary fibrosis: a multicenter retrospective cohort study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Chest.
Zaman T, Moua T, Vittinghoff E, Ryu JH, Collard HR, Lee JS
doi: 10.1016/j.chest.2020.02.009.
RECOMMENDED
COPD
Minimal clinically important differences for patient-reported outcome measures of fatigue in patients with COPD after pulmonary rehabilitation
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Chest.
Rebelo P, Oliveira A, Andrade L, Valente C, Marques A
doi: 10.1016/j.chest.2020.02.045.
RECOMMENDED
Interstitial Lung DiseasePulmonary Fibrosis
Prognostic value of transbronchial lung cryobiopsy for the multidisciplinary diagnosis of idiopathic pulmonary fibrosis: a retrospective validation study
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med.
Tomassetti S, Ravaglia C, Wells AU, Cavazza A, Colby TV, Rossi G, Ley B, Ryu JH, Puglisi S, Arcadu A, Marchi M, Sultani F, Martinello S, Donati L, Gurioli C, Gurioli C, Tantalocco P, Hetzel J, Dubini A, Piciucchi S, Klersy C, Lavorini F, Poletti V
doi: 10.1016/S2213-2600(20)30122-3.
Pulmonary Fibrosis
Breath biomarkers in idiopathic pulmonary fibrosis: a systematic review
Respir Res.
Hayton C, Terrington D, Wilson AM, Chaudhuri N, Leonard C, Fowler SJ
doi: 10.1186/s12931-019-0971-8.
COMMENTED
Pulmonary Fibrosis
Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials
Lancet Respir Med.
Neighbors M, Cabanski CR, Ramalingam TR, Sheng XR, Tew GW, Gu C, Jia G, Peng K, Ray JM, Ley B, Wolters PJ, Collard HR, Arron JR
doi: 10.1016/
Idiopathic pulmonary fibrosis in a Swiss interstitial lung disease reference centre
Swiss Med Wkly.
Guler S, Zumstein P, Berezowska S, Pöllinger A, Geiser T, Funke-Chambour M
doi: 10.4414/smw.2018.14577.
RECOMMENDED
Pulmonary Fibrosis
Clinical Effectiveness of the Anti-Fibrotic Medications for Idiopathic Pulmonary Fibrosis
Am J Respir Crit Care Med.
Dempsey TM, Sangaralingham LR, Yao X, Sanghavi D, Shah ND, Limper AH
doi: 10.1164/rccm.
RECOMMENDED
Pulmonary Fibrosis
Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Res.
Holtze CH, Freiheit EA, Limb SL, Stauffer JL, Raimundo K, Pan WT, Flaherty KR, Kim HJ
doi: 10.1186/s12931-020-1315-4.